Overview

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

Status:
Terminated
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
Upsher-Smith Laboratories
Treatments:
Midazolam